BACKGROUND: This study aims to evaluate the safety and efficacy of Xuezhikang in the treatment of unstable angina pectoris (UAP) in patients with elevated liver enzymes caused by statins. METHODS:Ninety UAP patients with elevated liver enzymes (higher than 3-fold the upper limits of normal caused by statins) were randomly divided into 3 groups: withdrawal of simvastatin (group A), continued taking of simvastatin (group B) and switching to Xuezhikang capsules (group C). RESULTS:Blood lipids and high-sensitivity C-reactive protein (hs-CRP) were measured before and after treatment, and liver enzymes were measured every two weeks. As the liver enzymes of the patients in group A returned to normal, they could again undertake administration of simvastatin. If the liver enzyme levels remained abnormal at four weeks, polyene phosphatidylcholine would be added. The endpoint events of each group were followed-up. After treatment for 4 weeks, the liver enzymes decreased in all of the three groups and there was a significant difference (p < 0.05). However, at 8 weeks the liver enzymes showed no significant difference among the three groups (p > 0.05). The blood lipids and hs-CRP were both reduced in group B and C. The decreased triglyceride and hs-CRP levels and increased high-density lipoprotein cholesterol level in group C were more remarkable than those in group B (p < 0.05). The incidence rate of endpoint events in group A was the highest (p < 0.05) among the three groups. CONCLUSIONS:Xuezhikang is safe and effective in the treatment for UAP patients with elevated liver enzymes caused by statins. KEY WORDS: Liver enzymes; Simvastatin; Unstable angina pectoris; Xuezhikang capsules.
RCT Entities:
BACKGROUND: This study aims to evaluate the safety and efficacy of Xuezhikang in the treatment of unstable angina pectoris (UAP) in patients with elevated liver enzymes caused by statins. METHODS: Ninety UAP patients with elevated liver enzymes (higher than 3-fold the upper limits of normal caused by statins) were randomly divided into 3 groups: withdrawal of simvastatin (group A), continued taking of simvastatin (group B) and switching to Xuezhikang capsules (group C). RESULTS: Blood lipids and high-sensitivity C-reactive protein (hs-CRP) were measured before and after treatment, and liver enzymes were measured every two weeks. As the liver enzymes of the patients in group A returned to normal, they could again undertake administration of simvastatin. If the liver enzyme levels remained abnormal at four weeks, polyene phosphatidylcholine would be added. The endpoint events of each group were followed-up. After treatment for 4 weeks, the liver enzymes decreased in all of the three groups and there was a significant difference (p < 0.05). However, at 8 weeks the liver enzymes showed no significant difference among the three groups (p > 0.05). The blood lipids and hs-CRP were both reduced in group B and C. The decreased triglyceride and hs-CRP levels and increased high-density lipoprotein cholesterol level in group C were more remarkable than those in group B (p < 0.05). The incidence rate of endpoint events in group A was the highest (p < 0.05) among the three groups. CONCLUSIONS: Xuezhikang is safe and effective in the treatment for UAP patients with elevated liver enzymes caused by statins. KEY WORDS: Liver enzymes; Simvastatin; Unstable angina pectoris; Xuezhikang capsules.
Authors: Aneta Otocka-Kmiecik; Dimitri P Mikhailidis; Stephen J Nicholls; Michael Davidson; Jacek Rysz; Maciej Banach Journal: Prog Lipid Res Date: 2012-05-15 Impact factor: 16.195
Authors: Michael Miller; Neil J Stone; Christie Ballantyne; Vera Bittner; Michael H Criqui; Henry N Ginsberg; Anne Carol Goldberg; William James Howard; Marc S Jacobson; Penny M Kris-Etherton; Terry A Lennie; Moshe Levi; Theodore Mazzone; Subramanian Pennathur Journal: Circulation Date: 2011-04-18 Impact factor: 29.690
Authors: Matthias Briel; Noah Vale; Gregory G Schwartz; James A de Lemos; Furio Colivicchi; Frank R den Hartog; Petr Ostadal; Stella M Macin; Anho Liem; Ed Mills; Neera Bhatnagar; Heiner C Bucher; Alain J Nordmann Journal: Int J Cardiol Date: 2011-02-04 Impact factor: 4.164
Authors: Zongliang Lu; Wenrong Kou; Baomin Du; Yangfeng Wu; Shuiping Zhao; Osvaldo A Brusco; John M Morgan; David M Capuzzi; S Li Journal: Am J Cardiol Date: 2008-04-11 Impact factor: 2.778